Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study

@inproceedings{Xu2017SulfatinibAN,
  title={Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study},
  author={Jian-Ming Xu and Yan Wang and Yu Ling Chen and Ru Jia and Jie Li and Ji Fang Gong and Jing Li and Chuan Min Qi and Ye Hua and Cui Tan and Jian Wang and Ke Li and Yang Sai and Feng Zhou and Yong Xin Ren and Wei Qing and Hong Jia and Wei Guo Su and Lin Shen},
  booktitle={Oncotarget},
  year={2017}
}
Sulfatinib is a small molecule kinase inhibitor that targets tumor angiogenesis and immune modulation. This phase I study (NCT02133157) investigated the safety, pharmacokinetic characteristics, and preliminary anti-tumor activity of sulfatinib in patients with advanced solid tumors. The study included a dose-escalation phase (50-350 mg/day, 28-day cycle) with a Fibonacci (3+3) design, and a tumor-specific expansion phase investigating the tumor response to treatment. Two sulfatinib formulations… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 19 REFERENCES

Sulfatinib chemical structure and synthesis: US

Hutchison Medipharma Limited
  • Patent 8,946,249
  • 2015
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL